A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.

Condition:   Triple Negative Breast Neoplasms Interventions:   Drug: Durvalumab;   Drug: Selumetinib;   Drug: Capivasertib;   Drug: Danvatirsen;   Drug: Oleclumab;   Drug: Paclitaxel Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials